Concepts (199)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Iodide Peroxidase | 16 | 2013 | 203 | 1.930 |
Why?
|
| Thyroid Gland | 7 | 2022 | 270 | 1.760 |
Why?
|
| Triiodothyronine | 10 | 2015 | 339 | 1.020 |
Why?
|
| Thyroid Neoplasms | 2 | 2022 | 408 | 1.000 |
Why?
|
| Iodine Radioisotopes | 3 | 2022 | 134 | 0.850 |
Why?
|
| Hyperthyroidism | 2 | 2022 | 75 | 0.840 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2022 | 109 | 0.800 |
Why?
|
| Thyroxine | 7 | 2014 | 344 | 0.680 |
Why?
|
| Thyroid Hormones | 5 | 2013 | 321 | 0.630 |
Why?
|
| Thyroid Nodule | 2 | 2016 | 51 | 0.610 |
Why?
|
| Oxygen Consumption | 4 | 2015 | 239 | 0.550 |
Why?
|
| Hypothyroidism | 4 | 2015 | 232 | 0.550 |
Why?
|
| Thyroiditis, Suppurative | 1 | 2014 | 1 | 0.490 |
Why?
|
| Coccidioidomycosis | 1 | 2014 | 7 | 0.490 |
Why?
|
| Mitochondria | 2 | 2015 | 535 | 0.480 |
Why?
|
| Immunocompromised Host | 1 | 2014 | 140 | 0.450 |
Why?
|
| Hormone Replacement Therapy | 2 | 2014 | 77 | 0.450 |
Why?
|
| Liver | 5 | 2015 | 1230 | 0.430 |
Why?
|
| Practice Guidelines as Topic | 1 | 2016 | 1037 | 0.340 |
Why?
|
| Muscle Fibers, Skeletal | 1 | 2008 | 45 | 0.330 |
Why?
|
| PPAR gamma | 1 | 2008 | 66 | 0.330 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2012 | 378 | 0.320 |
Why?
|
| Liver Transplantation | 1 | 2014 | 1271 | 0.270 |
Why?
|
| Ubiquitin-Conjugating Enzymes | 1 | 2003 | 30 | 0.230 |
Why?
|
| Endoplasmic Reticulum | 1 | 2003 | 250 | 0.210 |
Why?
|
| Radiometry | 1 | 2022 | 53 | 0.210 |
Why?
|
| Adipose Tissue, Brown | 3 | 2012 | 80 | 0.210 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2022 | 188 | 0.210 |
Why?
|
| Observational Studies as Topic | 1 | 2022 | 48 | 0.200 |
Why?
|
| Risk Assessment | 2 | 2022 | 2264 | 0.200 |
Why?
|
| Homeostasis | 3 | 2015 | 409 | 0.190 |
Why?
|
| Energy Metabolism | 3 | 2007 | 271 | 0.190 |
Why?
|
| Enzyme Activation | 2 | 2012 | 692 | 0.170 |
Why?
|
| Humans | 22 | 2022 | 86678 | 0.170 |
Why?
|
| Evidence-Based Medicine | 1 | 2020 | 429 | 0.160 |
Why?
|
| Cell Line, Tumor | 2 | 2015 | 2426 | 0.160 |
Why?
|
| Incidence | 1 | 2022 | 1578 | 0.150 |
Why?
|
| Mice | 9 | 2013 | 11356 | 0.150 |
Why?
|
| Animals | 14 | 2014 | 26590 | 0.140 |
Why?
|
| Mice, Inbred C57BL | 4 | 2012 | 3095 | 0.140 |
Why?
|
| Insulin Resistance | 3 | 2014 | 377 | 0.140 |
Why?
|
| Mice, Knockout | 3 | 2009 | 1924 | 0.130 |
Why?
|
| Oxidation-Reduction | 1 | 2015 | 373 | 0.120 |
Why?
|
| Ventricular Dysfunction | 1 | 2013 | 28 | 0.120 |
Why?
|
| Metabolic Syndrome | 1 | 2014 | 142 | 0.110 |
Why?
|
| Cell Line | 4 | 2012 | 2469 | 0.110 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2013 | 114 | 0.110 |
Why?
|
| Leupeptins | 1 | 2012 | 21 | 0.110 |
Why?
|
| Lovastatin | 1 | 2012 | 29 | 0.110 |
Why?
|
| Doxorubicin | 1 | 2013 | 295 | 0.110 |
Why?
|
| Cells, Cultured | 4 | 2013 | 2819 | 0.100 |
Why?
|
| Myoblasts | 2 | 2008 | 31 | 0.100 |
Why?
|
| Models, Biological | 3 | 2007 | 1749 | 0.100 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2015 | 386 | 0.100 |
Why?
|
| Hematologic Neoplasms | 1 | 2014 | 329 | 0.100 |
Why?
|
| In Vitro Techniques | 1 | 2012 | 989 | 0.090 |
Why?
|
| Glucose | 1 | 2013 | 638 | 0.090 |
Why?
|
| HEK293 Cells | 1 | 2012 | 615 | 0.090 |
Why?
|
| Research Design | 1 | 2013 | 594 | 0.090 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2009 | 879 | 0.090 |
Why?
|
| Heart Ventricles | 2 | 2013 | 760 | 0.090 |
Why?
|
| Phospholipid Transfer Proteins | 1 | 2009 | 5 | 0.090 |
Why?
|
| Thermogenesis | 1 | 2009 | 34 | 0.090 |
Why?
|
| Chromans | 1 | 2008 | 30 | 0.080 |
Why?
|
| Liver Neoplasms | 1 | 2015 | 738 | 0.080 |
Why?
|
| Thiazolidinediones | 1 | 2008 | 82 | 0.080 |
Why?
|
| Fatty Liver | 1 | 2009 | 125 | 0.080 |
Why?
|
| United States | 2 | 2020 | 6681 | 0.080 |
Why?
|
| Obesity | 1 | 2014 | 964 | 0.080 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2007 | 93 | 0.080 |
Why?
|
| Kaempferols | 1 | 2007 | 3 | 0.080 |
Why?
|
| Pituitary Gland | 1 | 2007 | 117 | 0.070 |
Why?
|
| Lipid Metabolism | 3 | 2014 | 197 | 0.070 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2014 | 1375 | 0.070 |
Why?
|
| Bile Acids and Salts | 1 | 2006 | 61 | 0.070 |
Why?
|
| Parathyroid Hormone-Related Protein | 1 | 2005 | 12 | 0.070 |
Why?
|
| Growth Plate | 1 | 2005 | 11 | 0.070 |
Why?
|
| Neuropsychological Tests | 1 | 2007 | 502 | 0.070 |
Why?
|
| Models, Molecular | 2 | 2006 | 1286 | 0.060 |
Why?
|
| Thyrotoxicosis | 1 | 2004 | 18 | 0.060 |
Why?
|
| Recombinant Proteins | 2 | 2003 | 1015 | 0.060 |
Why?
|
| Immunohistochemistry | 1 | 2008 | 1753 | 0.060 |
Why?
|
| Binding Sites | 2 | 2005 | 1098 | 0.060 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2005 | 165 | 0.060 |
Why?
|
| Kinetics | 2 | 2004 | 1513 | 0.060 |
Why?
|
| Receptors, Adrenergic, beta | 1 | 2004 | 72 | 0.060 |
Why?
|
| Cycloheximide | 1 | 2003 | 56 | 0.060 |
Why?
|
| Protein Conformation | 1 | 2006 | 881 | 0.060 |
Why?
|
| Signal Transduction | 3 | 2014 | 3243 | 0.060 |
Why?
|
| Gene Expression Regulation | 2 | 2009 | 1921 | 0.060 |
Why?
|
| Insulin | 1 | 2008 | 1160 | 0.060 |
Why?
|
| Transforming Growth Factor beta | 1 | 2005 | 301 | 0.060 |
Why?
|
| Dimerization | 1 | 2003 | 143 | 0.060 |
Why?
|
| Proteins | 2 | 2005 | 777 | 0.060 |
Why?
|
| RNA, Messenger | 1 | 2008 | 1981 | 0.050 |
Why?
|
| Up-Regulation | 1 | 2005 | 715 | 0.050 |
Why?
|
| Trans-Activators | 1 | 2005 | 429 | 0.050 |
Why?
|
| Cloning, Molecular | 1 | 2003 | 646 | 0.050 |
Why?
|
| Myocardium | 1 | 2004 | 529 | 0.050 |
Why?
|
| Cyclic AMP | 3 | 2007 | 273 | 0.050 |
Why?
|
| Thyroid Diseases | 2 | 2013 | 104 | 0.050 |
Why?
|
| Adult | 3 | 2014 | 25659 | 0.040 |
Why?
|
| Female | 5 | 2014 | 44550 | 0.040 |
Why?
|
| Muscle, Skeletal | 3 | 2006 | 449 | 0.040 |
Why?
|
| Ultrasonography | 2 | 2013 | 695 | 0.040 |
Why?
|
| Male | 5 | 2013 | 40988 | 0.040 |
Why?
|
| Brain | 1 | 2007 | 2216 | 0.040 |
Why?
|
| Norepinephrine | 2 | 2009 | 167 | 0.040 |
Why?
|
| Muscle Cells | 2 | 2006 | 18 | 0.030 |
Why?
|
| Mice, Transgenic | 2 | 2013 | 1540 | 0.030 |
Why?
|
| RNA Interference | 2 | 2007 | 369 | 0.030 |
Why?
|
| Blotting, Western | 2 | 2009 | 782 | 0.030 |
Why?
|
| Thyroid Function Tests | 1 | 2014 | 119 | 0.030 |
Why?
|
| Iodine | 1 | 2013 | 43 | 0.030 |
Why?
|
| Glucose Clamp Technique | 1 | 2013 | 39 | 0.030 |
Why?
|
| Glucose Transporter Type 1 | 1 | 2013 | 20 | 0.030 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2013 | 64 | 0.030 |
Why?
|
| Models, Animal | 1 | 2013 | 263 | 0.030 |
Why?
|
| Transfection | 2 | 2005 | 896 | 0.030 |
Why?
|
| Gene Expression Profiling | 2 | 2009 | 1384 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2013 | 322 | 0.030 |
Why?
|
| Behavior, Animal | 1 | 2013 | 373 | 0.020 |
Why?
|
| Gene Expression | 2 | 2005 | 1284 | 0.020 |
Why?
|
| Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha | 1 | 2009 | 16 | 0.020 |
Why?
|
| Receptors, Leptin | 1 | 2009 | 32 | 0.020 |
Why?
|
| Transcription Factors | 2 | 2009 | 1565 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2013 | 1538 | 0.020 |
Why?
|
| Thiolester Hydrolases | 1 | 2009 | 14 | 0.020 |
Why?
|
| Body Temperature | 1 | 2009 | 124 | 0.020 |
Why?
|
| Microscopy, Electron | 1 | 2009 | 503 | 0.020 |
Why?
|
| Heat-Shock Proteins | 1 | 2009 | 179 | 0.020 |
Why?
|
| Adipocytes | 1 | 2009 | 155 | 0.020 |
Why?
|
| Cytodiagnosis | 1 | 2007 | 42 | 0.020 |
Why?
|
| Microscopy, Fluorescence | 1 | 2009 | 425 | 0.020 |
Why?
|
| Chalcones | 1 | 2007 | 2 | 0.020 |
Why?
|
| Cyclic AMP-Dependent Protein Kinase Type II | 1 | 2007 | 3 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2013 | 2706 | 0.020 |
Why?
|
| Stilbenes | 1 | 2007 | 25 | 0.020 |
Why?
|
| Thyroidectomy | 1 | 2007 | 170 | 0.020 |
Why?
|
| Adaptation, Physiological | 1 | 2009 | 306 | 0.020 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 1 | 2007 | 107 | 0.020 |
Why?
|
| Pregnancy | 1 | 2013 | 2894 | 0.020 |
Why?
|
| Cholic Acid | 1 | 2006 | 7 | 0.020 |
Why?
|
| Elongin | 1 | 2005 | 2 | 0.020 |
Why?
|
| beta-Transducin Repeat-Containing Proteins | 1 | 2005 | 5 | 0.020 |
Why?
|
| Adiposity | 1 | 2006 | 70 | 0.020 |
Why?
|
| Smad Proteins | 1 | 2005 | 39 | 0.020 |
Why?
|
| Two-Hybrid System Techniques | 1 | 2005 | 55 | 0.020 |
Why?
|
| Chondrocytes | 1 | 2005 | 60 | 0.020 |
Why?
|
| Immunoprecipitation | 1 | 2005 | 134 | 0.020 |
Why?
|
| Hemangioma | 1 | 2005 | 60 | 0.020 |
Why?
|
| Dietary Fats | 1 | 2006 | 135 | 0.020 |
Why?
|
| Chick Embryo | 1 | 2005 | 229 | 0.020 |
Why?
|
| Tibia | 1 | 2005 | 82 | 0.020 |
Why?
|
| Protein Subunits | 1 | 2005 | 122 | 0.020 |
Why?
|
| Carbon Dioxide | 1 | 2006 | 188 | 0.020 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2006 | 115 | 0.020 |
Why?
|
| Hedgehog Proteins | 1 | 2005 | 93 | 0.020 |
Why?
|
| In Situ Hybridization | 1 | 2005 | 307 | 0.020 |
Why?
|
| Molecular Structure | 1 | 2005 | 287 | 0.020 |
Why?
|
| Ubiquitin | 1 | 2005 | 93 | 0.020 |
Why?
|
| Gene Deletion | 1 | 2006 | 329 | 0.020 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2005 | 416 | 0.020 |
Why?
|
| Estradiol | 1 | 2005 | 252 | 0.020 |
Why?
|
| Body Weight | 1 | 2006 | 459 | 0.020 |
Why?
|
| Colforsin | 1 | 2004 | 74 | 0.020 |
Why?
|
| Epithelium | 1 | 2005 | 319 | 0.020 |
Why?
|
| Adenylyl Cyclases | 1 | 2004 | 100 | 0.010 |
Why?
|
| GTP-Binding Proteins | 1 | 2004 | 146 | 0.010 |
Why?
|
| Selenium Radioisotopes | 1 | 2003 | 3 | 0.010 |
Why?
|
| Immunosorbent Techniques | 1 | 2003 | 13 | 0.010 |
Why?
|
| Dithiothreitol | 1 | 2003 | 26 | 0.010 |
Why?
|
| Isoenzymes | 1 | 2004 | 271 | 0.010 |
Why?
|
| Isotope Labeling | 1 | 2003 | 51 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2007 | 1992 | 0.010 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2005 | 379 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2007 | 1673 | 0.010 |
Why?
|
| Molecular Weight | 1 | 2003 | 332 | 0.010 |
Why?
|
| Disulfides | 1 | 2003 | 64 | 0.010 |
Why?
|
| Mutation | 2 | 2005 | 3968 | 0.010 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2003 | 268 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2007 | 1961 | 0.010 |
Why?
|
| Catalysis | 1 | 2003 | 203 | 0.010 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2003 | 279 | 0.010 |
Why?
|
| Fibroblasts | 1 | 2005 | 729 | 0.010 |
Why?
|
| Structure-Activity Relationship | 1 | 2003 | 408 | 0.010 |
Why?
|
| Promoter Regions, Genetic | 1 | 2005 | 937 | 0.010 |
Why?
|
| Myocytes, Cardiac | 1 | 2004 | 275 | 0.010 |
Why?
|
| Protein Binding | 1 | 2005 | 1457 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2005 | 2062 | 0.010 |
Why?
|
| Heart | 1 | 2004 | 539 | 0.010 |
Why?
|
| Cell Membrane | 1 | 2004 | 666 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 2005 | 1135 | 0.010 |
Why?
|
| Rats | 1 | 2007 | 3992 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2005 | 3030 | 0.010 |
Why?
|
| Middle Aged | 2 | 2009 | 25040 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2005 | 1458 | 0.010 |
Why?
|
| Adolescent | 1 | 2007 | 8984 | 0.010 |
Why?
|
| Aged | 1 | 2007 | 18423 | 0.010 |
Why?
|